| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_08cf2427e99e8a93a03572c033b77639
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3222eb0da9e139296d18ff554640f757
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a49d6583f28814a5ef8bb1aa966c59f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fb206898453f5012a98a316d3637a704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_844d71e552588565f3da867b216e2dc1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c54dcdeff95e221bc905b0917ba3346b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e13cf25eb1bef6199475314477618b46 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-499
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-429 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-04 |
| filingDate |
2011-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_52e2134f7670d226e7ac5b5121397188
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29cd26b32039a61f641ca6f8bf3527d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_818c8e19feecef57559aba1628a67da8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5a41fa3f85fc3dd71bebb8c920db01f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae7cd6eb2146b60d2d6bb3efe392b947
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f5c72ff4e0ecdddbce9daaa14ebcded |
| publicationDate |
2013-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8404691-B2 |
| titleOfInvention |
Imidazothiazole derivatives having proline ring structure |
| abstract |
There is provided compounds that inhibit interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity. Compounds include imidazothiazole derivatives that can inhibit interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity. |
| priorityDate |
2009-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |